Abstracts tagged "calcinosis"

Abstract Number: 1586 • ACR Convergence 2024
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Matthew Wells¹, Robyn Domsic², Ami Shah³, Laura Hummers⁴, Aishwarya Anilkumar¹, Tracy Frech⁵, Ariane Herrick⁶, Christopher Denton⁷, Dinesh Khanna⁸ and John Pauling¹, ¹North Bristol NHS Trust, Bristol, United Kingdom, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Manchester, UK, Aberdeen, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Telangiectasia are permanently dilated dermal postcapillary venules and are the 2nd most common manifestation (~80%) of systemic sclerosis (SSc) after Raynaud’s phenomenon (RP). The…
Abstract Number: 2069 • ACR Convergence 2024
Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort
Lovely Kumari¹, VISHNU KONERU², subin Philip¹, sai Kumar Dunga³, Mamatha gorijavulu⁴, Aishwarya Gopal⁵, Christina Mariaselvam⁶, Molly Thabah⁷, Vir Singh Negi⁸ and Chengappa Kavadichanda⁹, ¹JIPMER,PUDUCHERRY, PUDUCHERRY, Puducherry, India, ²JIPMER,PUDUCHERRY, PUDUCHERRY, India, ³JIPMER,PUDUCHERRY, VIZAG, Andhra Pradesh, India, ⁴JIPMER,PUDUCHERRY, HYDERABAD, Andhra Pradesh, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁶JIPMER, Puducherry, Puducherry, India, ⁷Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ⁸AIIMS BILASPUR, BILASPUR, Himachal Pradesh, India, ⁹Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India
Background/Purpose: Idiopathic inflammatory myopathy (IIM) carries an elevated cancer risk. The International Myositis Assessment and Clinical Studies Group (IMACS) has issued evidence-based guidelines for cancer…
Abstract Number: 2688 • ACR Convergence 2024
HLA-DRB4: A Novel Susceptibility Locus in Systemic Sclerosis Patients with Severe Calcinosis
Sara Faghihi-Kashani¹, srijana davluri², Kamini Kuchinad³, Zuoming deng⁴, Faiza Naz⁴, Stefania Dell'Orso⁴, Zsuzsanna McMahan⁵, Laura Hummers⁶, Daniel Kastner⁷, Fredrick Wigley³, david fiorentino⁸, Christian Lood⁹, Ami Shah¹⁰, Lorinda Chung¹¹ and Pravitt Gourh⁴, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, Sunnyvale, CA, ³Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁷National Human Genome Research Institute, Bethesda, MD, Bethesda, MD, ⁸Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ⁹Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, ¹⁰Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ¹¹Stanford University, Woodside, CA
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease. Class II HLA alleles have been reported to play an important role in SSc pathogenesis. Calcinosis, deposition of…
Abstract Number: 1525 • ACR Convergence 2023
Chelation Therapy in the Management of Calcinosis Associated with Systemic Sclerosis
Alison Fernandes, Ashraf El-Meanawy and ME Csuka, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Calcinosis is a common complication of systemic sclerosis (SSc), though effective treatment options are limited. Of the several medical therapies that have been employed…
Abstract Number: 2360 • ACR Convergence 2023
Systemic Sclerosis Macrophages Stimulate Calcinosis in Adipose Derived Mesenchymal Stem Cells via the Activin a Pathway
Tamara Searle¹, Ujvalla Kalluri¹, Sonia Ahmad², Bahja Ahmed Abdi¹, Sandra Lopez¹, Shiwen Xu¹, Teresa Collins¹, Jennifer Cross³, George Martin⁴, Henry Lopez⁵, Clayton Yates⁶ and Richard Stratton¹, ¹University College London, London, United Kingdom, ²Holy Family Red Crescent Medical College, Dhaka, Bangladesh, ³Aurinia Pharmaceuticals Inc., Rockford, MD, ⁴Riptide Bioscience Inc., Bethesda, MD, ⁵Riptide Bioscience Inc., Valejo, CA, ⁶Tuskegee University, Tuskegee, AL
Background/Purpose: Calcinosis may result from localised trans-differentiation of tissue resident stem cells in the subcutaneous layer of affected skin in systemic sclerosis (SSc), as a…
Abstract Number: 0284 • ACR Convergence 2023
Phenotyping Calcinosis: A Rare Manifestation of Rare Diseases
Michele Diomedi¹, Federico Fattorini¹, Simone Barsotti², Elenia Laurino¹, Chiara Cardelli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare systemic autoimmune disorders, with a pleiotropic clinical picture, specifically characterized from the inflammatory involvement of striate muscles. Calcinosis…
Abstract Number: 0301 • ACR Convergence 2023
Inflammatory Myopathies and Their Relationship with Cancer in a Colombian Cohort
Bolaños Juan D.¹, Rivera-Londoño Robert¹, Ivana Nieto-Aristizabal¹, Karol Enriquez², Santiago Zura², Alex Echeverri¹, Andrés Hormaza-Jaramillo¹ and David Aguirre-Valencia¹, ¹Fundación Valle del Lili, Cali, Colombia, ²Universidad ICESI, Cali, Colombia
Background/Purpose: Inflammatory myopathies (IM) constitute a heterogeneous group of autoimmune muscle diseases. These can occur in isolation, associated with other autoimmune disorders, or as a…
Abstract Number: 0610 • ACR Convergence 2023
Nailfold Capillaroscopy for Prediction of Novel Severe Organ Involvement in Systemic Sclerosis
Cristiana Sieiro Santos¹, Rúben Rego Salgueiro², Clara Moriano Morales³, Carolina Álvarez Castro³ and Elvira Díez Álvarez³, ¹Complejo Asistencial Universitario de León, León, Spain, ²ULS Guarda, Guarda, Portugal, ³CAULE, León, Spain
Background/Purpose: Nailfold capillaroscopy (NFC) has been suggested as a potential biomarker of disease severity in systemic sclerosis (SSc). Several studies report the association between capillary…
Abstract Number: 0616 • ACR Convergence 2023
Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study
Lea Meir¹, Tegveer Sandhu², Weiwei Chi² and Gabriela Santiago², ¹Icahn School of Medicine, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Systemic Sclerosis is an autoimmune disorder marked by thickened and hardened skin. Cutaneous cutis, the deposition of insoluble calcium salts in the skin and…
Abstract Number: 0992 • ACR Convergence 2023
Association Between Metabolic Syndrome and the Presence of Enthesophytes on Musculoskeletal Ultrasound Compared to Joint X-ray
Sean Brown¹, John Hardin² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Enthesophytes consist of calcium deposition on tendons or ligaments that are proposed to form in response to localized inflammation of the enthesis, either idiopathic…
Abstract Number: 1246 • ACR Convergence 2023
Assessment and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis
Belina Yi¹, Dawn Wahezi², Lauren Covert³, Kaveh Ardalan⁴, Joyce Hui-Yuen⁵, Natalia Vasquez Canizares⁶, Doaa Mosad Mosa⁷, Madison Jones⁸, Colleen Correll⁹, Alexis Begezda¹⁰, Susan Shenoi¹¹, Eveline Wu¹², Leonard Kovalick¹³, William Lapin¹⁴, Stacey Tarvin¹⁵, Melissa Oliver¹⁶, Martha Rodriguez¹⁷, Itay Marmor¹⁸, Kevin Baszis¹⁹, Alysha Taxter²⁰, Andrew Hanson²¹, Cynthia Crowson²² and Amir Orandi²², ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital at Montefiore, New Rochelle, NY, ³Duke University, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵North Shore LIJ Health System, Great Neck, NY, ⁶Children's Hospital at Montefiore, New York, NY, ⁷Mansoura University Hospitals, Mansoura University Faculty of Medicine, Mansoura city, Egypt, ⁸Keck School of Medicine of University of Southern California, Los Angeles, CA, ⁹University of Minnesota, Minneapolis, MN, ¹⁰Penn State, Hummelstown, PA, ¹¹Seattle Childrens Hospital, Mercer Island, WA, ¹²University of North Carolina School of Medicine, Chapel Hill, NC, ¹³UNC Health Care, Durham, NC, ¹⁴Connecticut Children's, Hartford, CT, ¹⁵Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ¹⁶Indiana University, Indianapolis, IN, ¹⁷Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁸Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ¹⁹Washington Univ in St. Louis School of Medicine, St. Louis, MO, ²⁰Nationwide Children's, Columbus, OH, ²¹Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ²²Mayo Clinic, Rochester, MN
Background/Purpose: Calcinosis is a poorly understood and morbid complication of juvenile dermatomyositis (JDM). As there is no consensus treatment approach for calcinosis, and limited knowledge…
Abstract Number: 1255 • ACR Convergence 2023
Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort
Sarah Molina¹, Dawn Gist², Marietta De Guzman³, Eyal Muscal⁴, Jamie Lai² and Maria Pereira³, ¹Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, ²Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory myopathy with clinically heterogeneous presentations that can be categorized by myositis-specific antibodies (MSAs). NXP2 is among…
Abstract Number: 008 • 2023 Pediatric Rheumatology Symposium
Treatment Response and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis
Belina Yi¹, Dawn Wahezi², Lauren Covert³, Kaveh Ardalan⁴, Joyce Hui-Yuen⁵, Natalia Vasquez Canizares², Doaa Mosad Mosa⁶, Madison Jones⁷, Colleen Correll⁸, Alexis Begezda⁹, Susan Shenoi¹⁰, Eveline Wu¹¹, Leonard Kovalick¹², William Lapin¹³, Stacey Tarvin¹⁴, Melissa Oliver¹⁵, Martha Rodriguez¹⁴, Itay Marmor¹⁶, Kevin Baszis¹⁷, Alysha Taxter¹⁸, Andrew Hanson¹⁹, Cynthia Crowson¹⁹ and Amir Orandi¹⁹, ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital at Montefiore, New York, NY, ³Duke University, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁶Mansoura University Hospitals, Mansoura University Faculty of Medicine, El Mansoura, Egypt, ⁷Keck School of Medicine at University of Southern California, Los Angeles, CCA, ⁸University of Minnesota, Minneapolis, MN, ⁹Penn State, State College, PA, ¹⁰Seattle Children's Hospital, Seattle, WA, ¹¹UNC Chapel Hill, Chapel Hill, NC, ¹²UNC Health Care, Durham, NC, ¹³Connecticut Children's, Hartford, CT, ¹⁴Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ¹⁵Indiana University, Indianapolis, IN, ¹⁶Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ¹⁷Washington University School of Medicine, St Louis, MO, ¹⁸Nationwide Children's Hospital, Columbus, OH, ¹⁹Mayo Clinic, Rochester, MN
Background/Purpose: Calcinosis is a poorly understood and morbid complication of juvenile dermatomyositis (JDM). As there is no consensus treatment approach for calcinosis, and limited knowledge…
Abstract Number: 027 • 2023 Pediatric Rheumatology Symposium
Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa
Jessica Perfetto¹, Laura Lewandowski², Dawn Wahezi¹, Christiaan Scott³ and Angela Migowa⁴, ¹Children's Hospital at Montefiore, New York, NY, ²NIAMS, NIH, Bethesda, MD, ³Red Cross War Memorial Children's Hospital, ⁴Aga Khan University, Nairobi, Kenya
Background/Purpose: There is a paucity of data on pediatric rheumatic disease (PRD) in low and middle-income countries (LMIC), creating a false perception of low prevalence…
Abstract Number: 0150 • ACR Convergence 2022
Growth and Differentiation Factor 15, an Emerging Biomarker of Mitochondrial Dysfunction- Associated Myopathies: Implications for Juvenile Dermatomyositis
Bhargavi Duvvuri¹, Lauren Pachman², Gabrielle Morgan³, Payton Hermanson⁴, TING WANG⁴ and Christian Lood⁴, ¹University of Washington, Seattle, WA, ²Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL, ³Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Our prior work has demonstrated mitochondrial involvement in JDM including the accumulation of calcified mitochondria in affected muscle tissue, and elevated levels of circulating…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].